Edition:
United States

Agenus Inc (AGEN.PH)

AGEN.PH on Philadelphia Stock Exchange

5.57USD
29 Jul 2016
Change (% chg)

$0.18 (+3.34%)
Prev Close
$5.39
Open
$5.41
Day's High
$5.70
Day's Low
$5.39
Volume
44,931
Avg. Vol
16,380
52-wk High
$8.66
52-wk Low
$2.65

Latest Key Developments (Source: Significant Developments)

Agenus Q2 loss per share $0.33
Thursday, 28 Jul 2016 08:50am EDT 

Agenus Inc : Qtrly revenue $6.6 million versus $6.4 million . Agenus reports second quarter 2016 financial results and operational progress . Q2 loss per share $0.33 . Q2 earnings per share view $-0.34 -- Thomson Reuters I/B/E/S .Q2 revenue view $5.1 million -- Thomson Reuters I/B/E/S.  Full Article

Agenus' chief financial officer, C.Evan Ballantyne to resign
Tuesday, 19 Jul 2016 08:51am EDT 

Agenus Inc : On july 14, 2016, C. Evan Ballantyne, chief financial officer informed agenus of his intention to resign - sec filing .Christin Klaskin, Agenus' VP, finance and principal accounting officer, will retain her roles, assume role of principal financial officer.  Full Article

Agenus Inc starts phase 1/2 clinical trial of anti-GITR agonist antibody
Wednesday, 22 Jun 2016 08:50am EDT 

Agenus Inc : Expect to initiate additional clinical studies with antibodies and immuno-oncology leads from comprehensive pipeline in next twelve months .Agenus announces commencement of phase 1/2 clinical trial of anti-GITR checkpoint antibody INCAGN1876 in patients with solid tumors.  Full Article

Agenus Inc acquires PhosImmune
Wednesday, 23 Dec 2015 08:00am EST 

Agenus Inc:Acquired privately-held PhosImmune Inc., a company that has discovered an entirely new portfolio of cancer neoantigens.The acquisition provides Agenus the ability to accelerate the development of new cancer vaccines and other single agent immuno-oncology approaches, as well as combination therapies.Under the terms of the agreement, Agenus paid PhosImmune's equity holders an upfront payment of $2.5 million in cash and $7.4 million in shares of Agenus common stock at closing.Additional payments of up to $35 million in cash and/or stock at Agenus' election are payable upon the achievement of certain.  Full Article

Agenus to acquire antibody manufacturing capability and capabilities from XOMA
Thursday, 5 Nov 2015 04:00pm EST 

Agenus Inc:To acquire biologics manufacturing facility and capabilities from XOMA.Acquires rights to Selexis cell line development technology.Purchases an exclusive license to a Phage Display library from Iontas.Under the terms of the agreement with XOMA, Agenus will pay at closing $5.0 million in cash and up to $1.0 million in common stock.  Full Article

Agenus Inc acquires novel antibodies to immuno-oncology Target CEACAM1
Monday, 20 Jul 2015 07:00am EDT 

Agenus Inc:Has acquired rights to antibodies targeting Carcinoembryonic Antigen Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein expressed on T cell and NK cell lymphocytes from Diatheva s.r.l.Antibodies targeting CEACAM1 are thought to have the potential to effectively treat cancer alone or in combination with other checkpoint modulator antibodies, including those in Agenus` development pipeline.Under license agreement, Agenus receives exclusive, worldwide rights for development and commercialization of CEACAM1 antibodies from Diatheva.Agenus is responsible for certain upfront, early development, clinical trial and regulatory milestone payments for successful development of CEACAM1 antibodies totaling as much as $44 mln.Diatheva is also eligible to receive additional sales milestones and royalties.  Full Article

Agenus appoints C. Evan Ballantyne as chief financial officer
Wednesday, 17 Jun 2015 07:00am EDT 

Agenus Inc:Appoints C. Evan Ballantyne as chief financial officer.  Full Article

Merck extends immuno-oncology collaboration with Agenus Inc
Wednesday, 3 Jun 2015 07:00am EDT 

Agenus Inc:Says discovery phase has been extended to April 2016.Merck will be responsible for the further development and commercialization of candidates generated under the collaboration.Agenus - Co will discover and optimize fully human antibodies against two undisclosed merck checkpoint targets using retrocyte display platform.  Full Article

Agenus Inc announces closing of public offering
Wednesday, 27 May 2015 04:01pm EDT 

Agenus Inc:Closes public offering of 12,650,000 shares of common stock, offered at price to public of $6.30 per share.Says Jefferies LLC and William Blair & Company, L.L.C. acted as joint book-running managers for the offering, and Oppenheimer & Co. Inc. acted as co-manager for the offering.  Full Article

Agenus Inc announces pricing of its public offering of common stock
Thursday, 21 May 2015 09:27am EDT 

Agenus Inc:Prices of an underwritten public offering of 11,000,000 shares of its common stock at a price to the public of $6.30 per share.Says gross proceeds from the offering to Agenus are expected to be $69,300,000, before deducting underwriting discounts and commissions and estimated offering expenses payable by Agenus.Agenus has granted the underwriters a 30-day option to purchase up to an additional 1,650,000 shares of its common stock at the public offering price, less the underwriting discount.Says all of the shares of common stock to be sold in the offering will be sold by Agenus.Jefferies LLC and William Blair & Company, L.L.C. are acting as joint book-running managers for the offering and Oppenheimer & Co. Inc. is acting as co-manager for the offering.Offering is expected to close on or about May 27.  Full Article

BRIEF-Agenus Q2 loss per share $0.33

* Agenus reports second quarter 2016 financial results and operational progress